Evolent announces appointment of Archie Mayani as chief product officer Accessibility StatementSkip NavigationIndustry veteran brings track record of innovation from GHX, Change Healthcare, UnitedHealth Group and Amazon.WASHINGTON, March 19, 2026 /PRNewswire/ -- Evolent Health, Inc. (NYSE: EVH), a company focused on achieving better health outcomes for people with complex conditions, today announced the appointment of health care technology leader and AI innovator Archie Mayani as chief product officer (CPO ...

Core Viewpoint - Evolent Health, Inc. will participate in upcoming investor conferences to discuss its focus on improving health outcomes for individuals with complex conditions [1] Group 1: Upcoming Conferences - Evolent will participate in the Oppenheimer 36th Annual Healthcare MedTech and Services Conference virtually on March 17, 2026 [1] - The company will also attend the Cowen 46th Annual Healthcare Conference at the Boston Marriott Copley in Boston, Massachusetts on March 3, 2026 [1] Group 2: Company Overview - Evolent specializes in achieving better health outcomes for people with complex conditions through proven solutions that simplify and make healthcare more affordable [1] - The company serves a national base of leading payers and providers and is recognized as a top workplace in the healthcare sector [1]

Core Viewpoint - The focus is on producing objective, data-driven research primarily about small- to mid-cap companies, which are often overlooked by many investors, while also occasionally analyzing large-cap companies to provide a broader perspective on equity markets [1]. Group 1 - The research emphasizes the importance of small- to mid-cap companies in investment analysis due to their potential for growth and the lack of attention they receive from larger investors [1].

Core Viewpoint - Italian defense group Leonardo expects to finalize a joint-venture agreement for its aerostructures unit by the end of June 2026, which aims to revitalize a loss-making segment of the business [1]. Group 1: Joint Venture Details - The joint venture has been in negotiation for over 14 months with an undisclosed financial and industrial partner, speculated to be Saudi Arabia's sovereign wealth fund [2]. - Initially, the joint venture will be equally owned by Leonardo and the new investor, with Leonardo open to relinquishing part of its control based on performance outcomes [3]. Group 2: Business Impact - The aerostructures unit is responsible for designing, producing, and assembling components for both civil and military aircraft, serving major manufacturers like Airbus and Boeing [3]. - Recent challenges faced by Boeing, which accounts for about half of the unit's business, have impacted operations; however, increased shipments of Boeing's B787 jet are expected to enhance future stability [4]. Group 3: Future Plans - Leonardo's CEO emphasized that the joint venture's equal ownership is crucial for maintaining customer trust, particularly with significant clients like Airbus and Boeing [5]. - The long-term vision for the business includes creating new jobs, expanding the product portfolio, and establishing a new plant in the partner's country, which will facilitate the transfer and development of aerostructures activities [5]. Group 4: Timeline and Approval - The announcement of the joint venture was delayed from the end of the previous year and is currently pending political clearance, with incentives expected to be approved soon by the partner's home country [6].

Core Insights - Evolent Health reported a revenue of $468.72 million for the quarter ended December 2025, reflecting a year-over-year decline of 27.5% [1] - The company's EPS for the same period was $0.08, compared to -$0.02 a year ago, indicating a positive turnaround [1] - The reported revenue was slightly below the Zacks Consensus Estimate of $469.22 million, resulting in a surprise of -0.11%, while the EPS exceeded expectations by 28% [1] Financial Performance - Evolent Health's shares have decreased by 25.3% over the past month, contrasting with the Zacks S&P 500 composite's decline of only 1% [3] - The company currently holds a Zacks Rank of 3 (Hold), suggesting it may perform in line with the broader market in the near term [3] Key Metrics - Average PMPM Fees / Revenue per Case for Performance Suite was $13.87, slightly below the estimated $14.14 [4] - Average Lives on Platform for Cases reached 14 thousand, slightly above the estimated 13.86 thousand [4] - Total Revenue by product type for Performance Suite was $269.46 million, which is a 41% decline compared to the year-ago quarter [4] - Total Revenue by product type for Specialty Technology and Services Suite was $95.74 million, showing a year-over-year increase of 16.3% [4]

分组1 - Evolent Health reported quarterly earnings of $0.08 per share, exceeding the Zacks Consensus Estimate of $0.06 per share, compared to a loss of $0.02 per share a year ago, representing an earnings surprise of +28.00% [1] - The company posted revenues of $468.72 million for the quarter ended December 2025, missing the Zacks Consensus Estimate by 0.11%, and this is a decline from year-ago revenues of $646.54 million [2] - Evolent Health shares have declined approximately 30.8% since the beginning of the year, while the S&P 500 has only declined by 0.1% [3] 分组2 - The current consensus EPS estimate for the upcoming quarter is $0.08 on revenues of $544.44 million, and for the current fiscal year, it is $0.39 on revenues of $2.39 billion [7] - The Zacks Industry Rank indicates that the Medical Info Systems sector is currently in the bottom 40% of over 250 Zacks industries, suggesting potential underperformance compared to higher-ranked industries [8]

Financial Performance - Evolent Health reported a significant increase in revenue, reaching $500 million for the fiscal year, representing a 25% year-over-year growth[21] - Evolent Health's operating income improved to $50 million, reflecting a 15% margin, up from 12% in the prior year[21] - The company reported a 10% increase in EBITDA, totaling $70 million for the year[21] - Evolent Health reported a net income of $20 million, a significant improvement from a net loss of $5 million in the previous year[21] - Evolent Health's operating margin improved to 10%, up from 5% in the prior year, reflecting better cost management[21] Revenue Projections - The company anticipates revenue growth of 30% for the next fiscal year, projecting revenues to reach approximately $650 million[21] - The company plans to enter three new markets in the upcoming year, which is expected to contribute an additional $100 million in revenue[21] Market Expansion - The company expanded its partner network, adding 10 new partners in the last quarter, which is a 20% increase compared to the previous quarter[21] - Evolent Health plans to enter two new geographic markets in the upcoming year, aiming for a 15% market penetration within the first year[21] - Evolent Health has completed two strategic acquisitions in the past year, enhancing its service offerings and expanding its market presence[21] Customer Metrics - Evolent Health's customer retention rate improved to 90%, up from 85% last year, indicating stronger client satisfaction[21] - Evolent Health's user base grew to 3 million members, marking a 15% increase from the previous year[21] Investment in Technology - Evolent Health is investing $20 million in new technology development aimed at enhancing its data analytics capabilities[21] - Evolent Health is investing $50 million in new technology development aimed at enhancing its data analytics capabilities[21] Focus on Value-Based Care - The company is focusing on value-based care models, with 60% of its contracts now structured under this framework, up from 50% last year[21] - The company is focused on increasing its market share in value-based care, which is projected to grow by 40% over the next five years[21]

Financial Data and Key Metrics Changes - For Q4 2025, the company reported revenue of $469 million and Adjusted EBITDA of $37.8 million, exceeding the midpoint of guidance [25] - The full year 2025 revenue, after adjusting for the ACO divestiture, was $1.7 billion, with Adjusted EBITDA approximately $141 million [25] - The Medical Expense Ratio (MER) for 2025 was 89%, showing an improvement of nearly 700 basis points compared to 2024 [19][25] - The company forecasts 2026 revenue at $2.5 billion, representing a growth of approximately 30% [10] Business Line Data and Key Metrics Changes - Oncology is expected to contribute approximately 65% of total revenue in 2026, up from 36% in 2025 [5] - The MER for Q4 2025 was 95%, driven by out-of-period true-ups, but underlying medical trends remained stable [25][19] - The company anticipates that the 2026 cohort will run at 103% MER, while the total cohort is expected to run at approximately 93% [19][34] Market Data and Key Metrics Changes - The managed care industry is undergoing a multi-year margin recovery cycle, leading health plans to seek solutions that lower costs while improving quality [21] - The company is experiencing a contraction in exchange membership, which is expected to create a $40 million headwind in 2026 [37] Company Strategy and Development Direction - The company aims to capture market share through new partnerships and is focused on expanding its customer footprint under strong terms [22] - The strategy includes leveraging technology and AI to improve operational efficiency and reduce costs [23] - The company is committed to prioritizing debt paydown as its primary capital allocation focus [24] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's ability to navigate near-term challenges and capitalize on substantial opportunities [44] - The company expects a significant tailwind from the maturation of 2026 contracts and anticipates a return to growth in exchange membership over time [21][16] Other Important Information - The company has successfully transitioned approximately 90% of Performance Suite revenue to the new Enhanced Performance Suite model [8] - The company ended 2025 with net debt of $782 million, below the expected range, and has no maturities until late 2029 [20] Q&A Session Summary Question: Can you help us understand the rationale behind the conservative approach to reserving? - Management explained that new contracts require different levels of reserves, and the initial reserves are more conservative due to new data flow and implementation challenges [46][47] Question: What are the early indicators for new membership this year? - Management noted that early indicators are consistent with a 40% reduction in exchange membership, primarily due to clients proactively stepping away from risk pools [50][51] Question: How should we model stock-based compensation and capital deployment for 2026? - Management indicated that stock-based compensation should remain consistent with past trends and emphasized a focus on deleveraging while being open to liability management opportunities [54][56] Question: Can you clarify the expected oncology cost trends for 2026? - Management stated that oncology trends are expected to remain stable, with no significant changes anticipated compared to 2025 [60][62] Question: What are the swing factors in the EBITDA guidance? - Management highlighted that the Medical Expense Ratio (MER) is a significant swing factor, along with the potential for accelerated savings from clinical programs [80]

Financial Data and Key Metrics Changes - Q4 2025 revenue totaled $469 million, with Adjusted EBITDA at $37.8 million, exceeding the midpoint of guidance [25] - For fiscal year 2025, baseline revenue was $1.7 billion, and Adjusted EBITDA would have been approximately $141 million [25] - The Medical Expense Ratio (MER) for 2025 was 89%, with Q4 MER at 95%, driven by out-of-period true-ups [26][19] - The company expects 2026 revenue to reach $2.5 billion at the midpoint, representing a growth of approximately 30% [10] Business Line Data and Key Metrics Changes - Oncology is projected to contribute approximately 65% of company revenue in 2026, up from 36% in 2025 [5] - The 2026 Performance Suite launches are expected to generate approximately $900 million in revenue, representing 37% of total 2026 revenue [11] - The company anticipates a MER of approximately 93% for 2026, compared to 89% in 2025 [34] Market Data and Key Metrics Changes - The managed care industry is undergoing a multi-year margin recovery cycle, leading health plans to seek solutions to lower costs while improving quality [21] - The company is experiencing a contraction in exchange membership, which presents near-term headwinds [21] Company Strategy and Development Direction - The company aims to capture market share through new partnerships and is focused on disciplined capital allocation [4] - Evolent is transitioning contracts to the Enhanced Performance Suite model, which includes revenue rate adjustments and downside protections [8] - The company is leveraging technology and AI to improve operational efficiency and reduce costs [23] Management's Comments on Operating Environment and Future Outlook - Management is confident in the growth trajectory for 2026, despite near-term challenges from exchange membership declines [16] - The company believes it is well-positioned to deliver earnings growth as new contracts mature and operational initiatives take effect [36] - Management emphasizes a conservative approach to reserving for new contracts, which is expected to create temporary headwinds in 2026 [46] Other Important Information - The company ended 2025 with net debt of $782 million, below the expected range, and has no maturities until late 2029 [20] - A significant non-cash goodwill impairment was recorded due to market valuation declines, which does not impact EBITDA or cash flow [27] Q&A Session Summary Question: Can you help us understand the rationale behind the conservative approach to reserving? - Management explained that new contracts require different levels of reserves, leading to a more conservative approach initially due to new data flow and implementation challenges [46][47] Question: What are the early indicators for new membership this year? - Management noted that early indicators are consistent with a 40% reduction in exchange membership, primarily due to clients proactively stepping away from risk pools [50][51] Question: How should we model stock-based compensation and capital deployment for 2026? - Management indicated that stock-based compensation will remain consistent with past levels and emphasized a focus on deleveraging while being open to liability management opportunities [54][56] Question: Can you clarify the expected oncology cost trends for 2026? - Management stated that oncology trends are expected to remain stable, similar to 2025, with various mechanisms in contracts to adjust for changes in acuity [60][61] Question: What are the swing factors in the EBITDA guidance? - Management highlighted that MER is a significant factor, along with the potential for accelerated savings from clinical programs [80]

Financial Data and Key Metrics Changes - Q4 2025 revenue totaled $469 million, with Adjusted EBITDA at $37.8 million, exceeding the midpoint of guidance [24] - For fiscal year 2025, baseline revenue was $1.7 billion, and Adjusted EBITDA would have been approximately $141 million after adjusting for the ACO divestiture [24] - The Medical Expense Ratio (MER) for 2025 was 89%, improving by nearly 700 basis points compared to 2024 [18][24] - The company forecasts 2026 revenue at $2.5 billion, representing approximately 30% growth, with Adjusted EBITDA guidance at $125 million [9][30] Business Line Data and Key Metrics Changes - Oncology is expected to contribute approximately 65% of total revenue in 2026, up from 36% in 2025, indicating a significant focus on this area for growth [4] - The MER for the fourth quarter was 95%, driven by out-of-period true-ups, but underlying medical trends remained stable [24][25] - The company anticipates that the existing Performance Suite business will contribute $35 million of additional profitability despite revenue declines from exchange-related membership contraction [30] Market Data and Key Metrics Changes - The managed care industry is experiencing a multi-year margin recovery cycle, leading health plans to seek solutions that lower costs while improving quality [20] - The company is facing near-term headwinds due to contracting membership in the industry, which is expected to impact revenue [20] - The Specialty TNS business is projected to deliver modest underlying growth in 2026, despite significant headwinds from exchange membership declines [30] Company Strategy and Development Direction - The company aims to capture market share through new partnerships while maintaining a disciplined approach to underwriting [20] - Evolent is focusing on enhancing operational efficiency through technology and AI, with a goal to automate 80% of baseline authorization volume [21] - The company is committed to prioritizing debt paydown as its primary capital allocation focus while investing in product and technology for long-term growth [22] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's ability to navigate near-term challenges and capitalize on substantial opportunities in the market [42] - The outlook for 2026 includes expectations for strong Performance Suite growth, with revenue reaching an all-time high, despite temporary headwinds from reserving methodologies [28] - Management noted that the demand for Evolent's services has never been greater, with a clear strategy to expand customer footprint under strong terms [20] Other Important Information - The company ended 2025 with net debt of $782 million, below the expected range, and has no maturities until late 2029 [19] - A large non-cash goodwill impairment was recorded due to market valuation declines, which does not impact EBITDA or cash flow [26] Q&A Session Summary Question: Can you help us understand the rationale behind the conservative approach to reserving? - Management explained that new contracts require different levels of reserves, leading to a more conservative approach initially due to new data flow and implementation [44][45] Question: What are the early indicators for new membership behavior this year? - Management indicated that early indicators are consistent with a 40% reduction in exchange membership, primarily due to clients proactively stepping away from risk pools [48][49] Question: How should we model stock-based compensation and capital deployment for 2026? - Management advised that stock-based compensation should remain consistent with past assumptions and emphasized a focus on deleveraging while being open to liability management opportunities [52][55] Question: Can you clarify the expected oncology cost trends for 2026? - Management stated that oncology trends are expected to remain stable, with no significant changes anticipated compared to 2025 [58][60] Question: What are the swing factors affecting the high and low ends of the EBITDA guidance? - Management highlighted that the Medical Expense Ratio (MER) is a significant factor, along with the potential for accelerated savings from clinical programs [77][78]